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BACKGROUND
Uncontrolled hypertension is a major problem among non-Hispanic black men, 
who are underrepresented in pharmacist intervention trials in traditional health 
care settings.
METHODS
We enrolled a cohort of 319 black male patrons with systolic blood pressure of 
140 mm Hg or more from 52 black-owned barbershops (nontraditional health care 
setting) in a cluster-randomized trial in which barbershops were assigned to a 
pharmacist-led intervention (in which barbers encouraged meetings in barber-
shops with specialty-trained pharmacists who prescribed drug therapy under a 
collaborative practice agreement with the participants’ doctors) or to an active 
control approach (in which barbers encouraged lifestyle modification and doctor 
appointments). The primary outcome was reduction in systolic blood pressure at 
6 months.
RESULTS
At baseline, the mean systolic blood pressure was 152.8 mm Hg in the intervention 
group and 154.6 mm Hg in the control group. At 6 months, the mean systolic 
blood pressure fell by 27.0 mm Hg (to 125.8 mm Hg) in the intervention group 
and by 9.3 mm Hg (to 145.4 mm Hg) in the control group; the mean reduction 
was 21.6 mm Hg greater with the intervention (95% confidence interval, 14.7 to 
28.4; P<0.001). A blood-pressure level of less than 130/80 mm Hg was achieved 
among 63.6% of the participants in the intervention group versus 11.7% of the 
participants in the control group (P<0.001). In the intervention group, the rate of 
cohort retention was 95%, and there were few adverse events (three cases of acute 
kidney injury).
CONCLUSIONS
Among black male barbershop patrons with uncontrolled hypertension, health 
promotion by barbers resulted in larger blood-pressure reduction when coupled 
with medication management in barbershops by specialty-trained pharmacists. 
(Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials 
.gov number, NCT02321618.)
A BS TR AC T
A Cluster-Randomized Trial of Blood-
Pressure Reduction in Black Barbershops
Ronald G. Victor, M.D., Kathleen Lynch, Pharm.D., Ning Li, Ph.D., 
Ciantel Blyler, Pharm.D., Eric Muhammad, B.A., Joel Handler, M.D., 
Jeffrey Brettler, M.D., Mohamad Rashid, M.B., Ch.B., Brent Hsu, B.S., 
Davontae Foxx-Drew, B.A., Norma Moy, B.A., Anthony E. Reid, M.D.,* 
and Robert M. Elashoff, Ph.D. 
Original Article
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF MARYLAND COLLEGE PARK on February 7, 2019. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;14 nejm.org April 5, 20181292
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Non-Hispanic black men have the highest rate of hypertension-related death of any racial, ethnic, or sex group in the 
United States.1,2 Black men have less physician 
interaction than black women3 and lower rates 
of hypertension treatment and control,2 necessi-
tating community outreach.
Health outreach to barbershops is well-estab-
lished but largely untested as to whether it im-
proves hypertension management in black men. 
One previous randomized trial showed slightly 
better blood-pressure reduction in black men 
when barbers checked blood pressure and urged 
patrons with elevated readings to make doctor 
appointments than when barbers only distrib-
uted hypertension pamphlets.4 The marginal 
intervention effect (between-group difference 
of −2.5 mm Hg in systolic blood pressure and 
−0.9 mm Hg in diastolic blood pressure) appeared 
due in part to design issues but also to the fact 
that clinicians rarely intensified drug therapy for 
these men,5 a reportedly common occurrence 
(with notable exceptions)6,7 in busy primary care 
practices in which doctors, patients, and health 
care systems have shared responsibility.8-11
Thus, we aimed to develop a potent — and 
convenient — blood-pressure control program 
for black men in which we linked health promo-
tion by barbers to drug treatment by pharma-
cists and evaluated the resultant efficacy in a 
cluster-randomized trial. Although more than 
40 randomized trials have provided evidence 
that hypertension control can be improved by 
the actions of pharmacists,12-17 the traditional 
health care settings used in such trials included 
few black men.
Here we screened black men who were pa-
trons of participating barbershops and enrolled 
a cohort with systolic blood-pressure levels of 
140 mm Hg or higher. The barbershops were 
cluster-randomized; in some shops, barbers pro-
moted follow-up with specialty-trained pharma-
cists (intervention group), whereas in other shops, 
barbers were trained to encourage lifestyle modi-
fication and doctor appointments (control group). 
In the intervention group, pharmacists met reg-
ularly with participants at the barbershops and 
prescribed and monitored a drug-intensification 
regimen and then sent notes on progress to the 
participants’ providers. The primary hypothesis 
was that the reduction in systolic blood pressure 
after 6 months would be greater among partici-
pants at barbershops with the pharmacist-led 
intervention.
Me thods
Trial Design and Oversight
In this trial, the barbershop was the unit of ran-
domization. Participant group was determined 
according to barbershop (Fig. 1; and Fig. S1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The trial 
was approved by institutional review boards at 
Cedars–Sinai Medical Center, Kaiser Permanente, 
and Westat (a survey company that conducted 
screening and enrollment and collected baseline 
and follow-up data), and the conduct of the trial 
was periodically reviewed by an independent 
data and safety monitoring board.18 Participants 
provided written informed consent. The authors 
vouch for the completeness and accuracy of the 
data and analyses and for the fidelity of the trial 
to the protocol, available at NEJM.org.
Trial Population
Field interviewers screened the clientele at par-
ticipating black-owned barbershops to recruit 
self-identified regular patrons (≥1 haircut every 
6 weeks for ≥6 months) who were non-Hispanic 
black men, 35 to 79 years of age, with systolic 
blood pressure of 140 mm Hg or more on two 
screening days (Fig. 1). Women and persons re-
ceiving dialysis or chemotherapy were excluded.
Randomization and Interventions
Cluster randomization was necessary to avoid 
between-group contamination and to account 
for intraclass correlation.19,20 Barbershops were 
assigned to the intervention or to the active con-
trol approach in a 1:1 ratio in equally balanced 
blocks of four with the use of a prespecified 
random-number sequence. Participants and field 
interviewers were aware of the randomization 
assignments of the barbershops.
Barbers in shops assigned to the intervention 
were trained to encourage pharmacist follow-up 
and measure blood pressure. Before pharmacist 
intervention, providers signed a collaborative 
practice agreement. (See the Supplementary Ap-
pendix.) Two full-time doctoral-level pharmacists 
received specialized training and certification as 
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hypertension clinicians and regularly reviewed 
each participant’s treatment with physician hy-
pertension specialists (the first, sixth, and sev-
enth authors). Pharmacists met regularly with 
participants in barbershops assigned to the inter-
vention; the pharmacists prescribed an antihyper-
tensive drug regimen, measured blood pressure, 
encouraged lifestyle changes, and monitored 
plasma electrolyte levels. The protocol called for 
the pharmacists to prescribe two-drug therapy 
that insurance would approve — preferably am-
lodipine plus a long-acting angiotensin-receptor 
blocker (ARB) or angiotensin-converting–enzyme 
(ACE) inhibitor — and to use the long-acting 
thiazide-type diuretic indapamide as the pre-
ferred third drug.21,22 Drug-class substitutions 
were allowed when medically indicated. After 
each encounter with a participant, pharmacists 
sent progress notes with their contact informa-
tion to the given participant’s health care provid-
er. If a given participant did not have a provider 
to sign the collaborative practice agreement, a 
designated community physician served as the 
supervising doctor.
Participants in the control group received in-
struction about blood pressure (Fig. S2 in the 
Supplementary Appendix). Barbers were trained 
to discuss the instructional information with 
participants and encourage follow-up with a 
provider.
Figure 1. Screening, Enrollment, and Follow-up of Barbershop Patrons.
Other exclusion criteria included infrequent barbershop patronage (duration of <6 months or more than every 6 weeks 
between visits), an age younger than 35 years or older than 79 years, current treatment with dialysis or cancer chemo-
therapy, or plans to relocate.
4567 Barbershop patrons were
eligible for screening
2626 Completed first screening at
barbershops assigned to the intervention
1941 Completed first screening at
barbershops assigned to the active control
2088 Were excluded
1494 Had systolic blood
pressure <140 mm Hg
594 Met other exclusion
criteria
1491 Were excluded
1077 Had systolic blood
pressure <140 mm Hg
414 Met other exclusion
criteria
538 Were eligible for second screening 450 Were eligible for second screening
399 Were excluded at second
screening
124 Had systolic blood
pressure <140 mm Hg
147 Were lost to follow-up
128 Declined participation
270 Were excluded at second
screening
118 Had systolic blood
pressure <140 mm Hg
109 Were lost to follow-up
43 Declined participation
139 Had uncontrolled hypertension
and were enrolled
132 Had complete 6-mo data 171 Had complete 6-mo data
7 Were lost to follow-up
1 Died
6 Withdrew
9 Were lost to follow-up
1 Died
8 Withdrew
180 Had uncontrolled hypertension
and were enrolled
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Participants in both groups received resources 
to promote cohort retention and blood-pressure 
reduction: the results of two blood-pressure screen-
ings, with follow-up recommendations and iden-
tification cards (Figs. S3 and S4 in the Supple-
mentary Appendix); follow-up calls at 3 months; 
culturally specific health sessions; and vouchers 
for monthly haircuts. In intervention-group shops 
only, pharmacists interviewed participants to 
generate peer-experience stories (posted on shop 
walls), reviewed blood-pressure trends (Figs. S5 
and S6 in the Supplementary Appendix), and 
gave participants $25 per pharmacist visit to 
offset the costs of generic drugs and transporta-
tion to pharmacies.
Trial Measurements
Field interviewers administered 30-minute, in-
person, computer-based questionnaires in barber-
shops to participants in both groups at baseline 
and 6 months. These interviewers recorded blood 
pressure and structured response data on base-
line characteristics, participant-reported outcomes, 
and prescription information transcribed from 
pill bottles.
All blood pressures were measured in barber-
shops with the use of a validated oscillometric 
monitor (Accutorr V, Mindray).23 To automate 
measurement and minimize dependence on op-
erators, monitor readings were directly uploaded 
to a computer that electronically transmitted data 
to a secure website. (See the protocol.) At each 
visit, five sequential blood-pressure readings were 
obtained; the first two readings were discarded, 
and the last three readings were averaged.4 To 
reduce regression to the mean, the second 
screening blood pressure was taken as the base-
line value.24 Field interviewers, pharmacists, and 
barbers were trained in proper measurement 
technique (with the participant seated after 5 min-
utes of rest and the arm resting at heart level and 
with no conversation with participants). The cor-
rect arm-cuff size was determined for each par-
ticipant at the first screening and used through-
out the trial.
For 6 months, pharmacists and some barbers 
measured blood pressure monthly to monitor 
drug therapy in the intervention group but not 
in the control group. The final 6-month blood 
pressures were recorded by field interviewers in 
the control group and by pharmacists in the inter-
vention group to minimize the alerting reaction 
evoked by an unfamiliar data collector. The pre-
specified blood-pressure goal was less than 
130/80 mm Hg — 5/5 mm Hg lower than the 
conventional out-of-office blood-pressure goal of 
less than 135/85 mm Hg25 — to account for 
blood-pressure variability. Pharmacists used a 
validated Clinical Laboratory Improvement Amend-
ments–waived point-of-care device (i-STAT, Ab-
bott Laboratories)26 to monitor plasma levels of 
electrolytes and creatinine after each medication 
change.
Trial Outcomes
Outcomes were measured as changes from base-
line to 6 months. The prespecified primary out-
come was systolic blood pressure. Secondary 
outcomes included diastolic pressure, rates of 
meeting blood-pressure goals, numbers of anti-
hypertensive drugs, adverse drug reactions, self-
rated health,3 and patient engagement according 
to a validated instrument.27 Acute kidney injury 
was defined as an increase in the plasma cre-
atinine level of at least 0.3 mg per deciliter 
(30 μmol per liter) or a level at least 1.5 times 
the baseline level.28
Statistical Analysis
With an enrollment target of 10 barbershop 
clusters per trial group — 25 participants per 
cluster, a rate of cohort retention of 70%, and an 
estimated intraclass correlation coefficient of 
0.014 — the initial design yielded 90% power to 
detect a 6.9 mm Hg greater reduction in systolic 
blood pressure at 6 months in the intervention 
group than in the control group, with a two-
sided alpha level of 0.05. Because the total num-
ber of patrons per barbershop was much lower 
than anticipated, we increased the number of 
shops and grouped low-enrolling shops into 
clusters according to both enrollment date and 
geographic proximity, yielding 10 shop-clusters 
per group with at least 10 participants per clus-
ter.29,30 The number of participants who with-
drew from the trial was very small (Fig. 1) and 
was considered to be random after extensive 
analysis.31
The intervention effect was estimated by 
means of a linear mixed-effects model, which 
included a random cluster effect. The primary 
predictor was an indicator for intervention group 
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versus control group. Given the sample size, the 
model included three baseline covariates: base-
line blood pressure, a doctor for routine medical 
care (yes vs. no), and high cholesterol level (yes 
vs. no). These were either strongly correlated 
with the dependent variable or showed baseline 
imbalance between the two groups. The linear 
mixed-effects model and its assumptions are 
described in the Supplementary Appendix.
R esult s
Trial Sites and Trial Participants
A total of 78 Los Angeles County barbershops 
completed 6 months of participation between 
February 2015 and July 2017; 26 shops that en-
rolled 0 or 1 participant were eliminated (Fig. S1 
in the Supplementary Appendix). We enrolled a 
cohort of 319 participants with systolic blood 
pressure of 140 mm Hg or higher from 52 black-
owned barbershops. The primary statistical analy-
sis is based on 132 participants in 28 interven-
tion shops and 171 participants in 24 control 
shops that completed a 6-month follow-up (Fig. 1). 
An intention-to-treat analysis that used the last 
measured blood pressure for 7 participants lost 
to follow-up in the intervention group was also 
performed; however, no adjustment for abbrevi-
ated treatment could be made in the control 
group, which had only baseline data on 9 par-
ticipants lost to follow-up (Fig. 1).
The two cluster-randomized groups were well 
balanced across most characteristics, except that 
a higher percentage of participants in the inter-
vention group than in the control group report-
ed having a high cholesterol level (Table 1, and 
Table S1 in the Supplementary Appendix). The 
rate of cohort retention was 95% in both groups 
(Fig. 1).
Primary Outcome
At baseline, the mean systolic blood pressure 
was 152.8 mm Hg in the intervention group and 
154.6 mm Hg in the control group (Table 2). 
At 6 months, the mean systolic pressure fell 
27.0 mm Hg (to 125.8 mm Hg) in the interven-
tion group versus 9.3 mm Hg (to 145.4 mm Hg) 
in the control group; the mean reduction in sys-
tolic blood pressure was 21.6 mm Hg greater in 
the intervention group than in the control group 
(95% confidence interval [CI], 14.7 to 28.4; 
P<0.001) (Table 2). The size of the intervention 
effect was similar in the intention-to-treat analy-
sis: the mean reduction was 21.0 mm Hg greater 
in the intervention group than in the control 
group (95% CI, 14.0 to 28.0; P<0.001) (Table S2 
in the Supplementary Appendix). The interven-
tion effect was consistent across clusters (Fig. 2).
Secondary Blood-Pressure Outcomes
The mean reduction in diastolic blood pressure 
was 14.9 mm Hg greater in the intervention 
group than in the control group (95% CI, 10.3 to 
19.6; P<0.001), with similar values in the inten-
tion-to-treat analysis (Table 2, and Table S2 and 
Fig. S7 in the Supplementary Appendix). Blood-
pressure goals were met by a higher percentage 
of participants in the intervention group than in 
the control group (Table 2, and Table S2 in the 
Supplementary Appendix).
Changes in Doctor Visits and Medication
The mean (±SD) number of doctor visits that par-
ticipants reported for the 3 months before base-
line was similar in the intervention and control 
groups (1.0±1.2 and 1.2±1.4, respectively), as was 
the mean number of visits between 3 months 
and 6 months after enrollment (1.2±1.5 and 
1.1±1.3, respectively). After 6 months, the use 
of antihypertensive medication increased from 
55% to 100% in the intervention group and from 
53% to 63% in the control group (P<0.001).
The intervention led to a greater number of 
antihypertensive drug classes per regimen and 
higher percentages of participants treated with 
preferred first-line and add-on drugs than did 
the active control (Table 3, and Table S3 in the 
Supplementary Appendix). In addition, partici-
pants in the intervention group were more likely 
than those in the control group to be treated 
with long-acting drugs such as amlodipine, irbe-
sartan or telmisartan (ARBs), and indapamide 
(Table S4 in the Supplementary Appendix).
Safety Outcomes
There were no treatment-related serious adverse 
events in either group. There was one death per 
group that was adjudicated by physician moni-
tors to be unrelated to trial participation. Chang-
es in medication side effects were similar in the 
two groups, with few exceptions (Table S5 in the 
Supplementary Appendix).
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In the intervention group, transient acute kid-
ney injury developed in three participants. In each 
case, the regimen included indapamide; the acute 
kidney injury resolved when indapamide was 
stopped (Table S6 in the Supplementary Appen-
dix). We had no data on acute kidney injury in 
the control group.
Patient-Reported Outcomes
Self-rated health and patient engagement in-
creased more in the intervention group than in 
the control group (Tables S7 and S8 in the Sup-
plementary Appendix). These patient-reported 
outcomes were assessed by means of validated 
instruments.3,27
Characteristic Intervention Group Control Group
Barbershops
No. of barbershops 28 24
Years in business 17.3±14.2 18.1±8.3
No. of barbers per shop 4±2 4±2
Participants
No. of participants 132 171
Age — yr 54.4±10.2 54.6±9.5
Married or living with a partner — no./total no. (%) 61/131 (46.6) 86/171 (50.3)
Highest educational level — no./total no. (%)
Not a high school graduate 6/131 (4.6) 13/171 (7.6)
High school graduate or GED equivalent 30/131 (22.9) 49/171 (28.7)
Some college or associate’s degree 67/131 (51.1) 76/171 (44.4)
Bachelor’s degree 21/131 (16.0) 23/171 (13.5)
Graduate or professional degree 7/131 (5.3) 10/171 (5.8)
Annual household income — no./total no. (%)
$0–$15,999 31/123 (25.2) 34/168 (20.2)
$16,000–$24,999 20/123 (16.3) 15/168 (8.9)
$25,000–$39,999 9/123 (7.3) 19/168 (11.3)
$40,000–$49,999 14/123 (11.4) 21/168 (12.5)
$50,000–$74,999 20/123 (16.3) 34/168 (20.2)
$75,000–$99,999 16/123 (13.0) 21/168 (12.5)
≥$100,000 13/123 (10.6) 24/168 (14.3)
Regular medical care provider — no./total no. (%) 101/131 (77.1) 134/170 (78.8)
Any health insurance — no. (%) 112 (84.8) 150 (87.7)
Barbershop patronage
Duration of patronage — yr 10.2±9.6 11.5±9.0
Frequency of visits — every no. of wk 2.0±0.9 2.1±1.1
Cardiovascular risk factors†
Body-mass index‡ 30.8±5.4 31.2±6.0
Current smoker — no./total no. (%) 43/130 (33.1) 51/171 (29.8)
Diabetes — no. (%) 28 (21.2) 38 (22.2)
High cholesterol level — no. (%) 46 (34.8) 41 (24.0)
*  Plus–minus values are means ±SD. There were no significant between-group differences (P<0.05), except for high cho-
lesterol level (P = 0.04). All data are unadjusted. GED denotes General Educational Development.
†  Risk factors were reported by the participants.
‡  The body-mass index is the weight in kilograms divided by the square of the height in meters. Both height and weight 
were reported by the participants.
Table 1. Baseline Characteristics of the Barbershops and Trial Participants.*
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Process Data
A total of 83 peer-experience stories were gener-
ated and posted in intervention shops (Fig. S5 in 
the Supplementary Appendix). In 6 months, each 
participant in the intervention group received on 
average seven in-person pharmacist visits and 
four follow-up telephone calls from the pharma-
cist and messaged or called the pharmacist six 
times. Barbers checked blood pressure in 6 of 
the 28 intervention shops (average of four checks 
per participant in these 6 shops) and discussed 
health lessons in 10 of the 24 control shops 
(average of four lessons per participant in these 
10 shops).
Discussion
Among black men who were barbershop patrons 
with uncontrolled hypertension, health promo-
tion by barbers resulted in larger reductions in 
blood pressure when coupled with drug therapy 
prescribed by specialty-trained pharmacists. The 
mean reductions in systolic and diastolic blood 
pressure were 21.6 and 14.9 mm Hg greater, 
respectively, in participants assigned to the 
pharmacist-led intervention than in those as-
signed to the active control. In the intervention 
group, the rate of cohort retention was 95%, 
there were few adverse events, and self-rated 
health and patient engagement increased.
The major strengths of the trial are the inter-
vention effect itself and the high cohort reten-
tion. For a community-level trial with a tradi-
tionally difficult-to-reach, mainly low-income 
male population, the net intervention effect on 
systolic blood pressure was large — an order of 
magnitude larger than the −2.5 mm Hg effect 
in our previous barbershop trial4 and 3 times 
larger than the average −7 mm Hg effect in 
pharmacist intervention trials12-17 involving men 
with similar baseline systolic blood-pressure 
levels (approximately 150 mm Hg).14-17
The intervention increased the use of anti-
hypertensive drugs. The interventional pharma-
cists prescribed more combination drug therapy 





(N = 171) Intervention Effect P Value†
Blood pressure
Systolic blood pressure — mm Hg‡
At baseline 152.8±10.3 154.6±12.0
At 6 mo 125.8±11.0 145.4±15.2
Change −27.0±13.7 −9.3±16.0 −21.6 (−28.4 to −14.7)§ <0.001
Diastolic blood pressure — mm Hg
At baseline 92.2±11.5 89.8±11.2
At 6 mo 74.7±8.3 85.5±12.0
Change −17.5±11.0 −4.3±11.8 −14.9 (−19.6 to −10.3)§ <0.001
Hypertension control at 6 mo — no. (%)
Blood pressure <140/90 mm Hg 118 (89.4) 55 (32.2) 3.4 (2.5 to 4.6)¶ <0.001
Blood pressure <135/85 mm Hg 109 (82.6) 32 (18.7) 5.5 (2.6 to 11.7)¶ <0.001
Blood pressure <130/80 mm Hg 84 (63.6) 20 (11.7) 5.7 (2.5 to 12.8)¶ <0.001
*  Plus–minus values are means ±SD.
†  For systolic blood pressure and diastolic blood pressure, P values were calculated from linear mixed-effects models 
with random intercepts for clusters. The estimated intervention effect was controlled for baseline systolic or diastolic 
blood pressure, routine doctor, and high cholesterol level. For hypertension control at 6 months, P values were calcu-
lated from generalized estimating equations with a compound symmetry working correlation to account for cluster ef-
fects. The estimated intervention effect was controlled for baseline systolic blood pressure, routine doctor, and high 
cholesterol level.
‡  The prespecified primary outcome was the change in systolic blood pressure from baseline to 6 months. The intraclass 
correlation coefficient from the linear mixed-effects model for change in systolic blood pressure was 0.05. Degrees of 
freedom for the estimated intervention effect = 276.
§  Shown is the difference in mean change in blood pressure and 95% confidence interval.
¶  Shown is the relative risk and 95% confidence interval.
Table 2. Primary and Secondary Blood-Pressure Outcomes.*
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munity practitioners treating men in the control 
group. The starting combination of amlodipine–
ARB or amlodipine–ACE inhibitor in the present 
trial was effective; fewer than half of individual 
patient regimens involved three or more drugs.
The effectiveness of the intervention was 
probably multifaceted. Pharmacists made drug 
therapy convenient by bringing it to the barber-
shop. The intervention was tailored to black men 
and endorsed by the involved barbers — trusted 
community members (as evidenced in the peer-
experience stories). That loyal patrons of barber-
shops are consistent in their visits (every 2 weeks 
for a decade) facilitated hypertension manage-
ment in the present trial. Because most patrons 
in the present trial lived alone, we speculate that 
peer support at the barbershop facilitated health 
promotion.
The intervention was implemented largely as 
intended, but specific elements evolved to meet 
unexpected challenges. Regimen intensification 
showed pharmacist fidelity to the medication 
protocol. The 83 peer-experience posters showed 
fidelity to the behavior theory (peer learning).4,32 
Because the total clientele size of the barber-
shops was much smaller than expected, one 
barbershop owner (the fifth author) recruited 
approximately 4 times the originally planned 
number of barbershops. Because barbers did not 
consistently check blood pressure, pharmacists 
assumed this role. Because 40% of the partici-
pants did not have a doctor to sign the collab-
orative practice agreement, one main commu-
nity physician (the next-to-last author) served 
as their supervising doctor. To avoid delays in 
laboratory testing, our pharmacists monitored 
Figure 2. Systolic Blood Pressure at Baseline and 6 Months According to Barbershop Cluster.
Shown are box plots for systolic blood pressure according to barbershop cluster. The horizontal line inside each box indicates the median, 
the diamond indicates the mean, and the bottom and top of each box indicate the 25th percentile and 75th percentile, respectively. I bars 
indicate the upper adjacent value (75th percentile plus 1.5 times the interquartile range) and the lower adjacent value (25th percentile 
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plasma electrolyte levels at the point of care — 
the barbershop.
Our trial has several limitations. The assign-
ment through cluster randomization could not 
be blinded; however, the intervention was evalu-
ated by independently contracted field interview-
ers, and blood-pressure measurement and trans-
mission of the values obtained were automated 
and standardized to minimize interobserver vari-
ability. Confounding may have led to overestima-
tion of the effect size of the intervention. Pharma-
cists targeted an in-barbershop blood pressure 
of less than 130/80 mm Hg for the participants 
in the intervention group, whereas primary care 
providers probably targeted an in-office blood 
pressure of less than 140/90 mm Hg33,34 for most 
participants in the control group. Normotensive 
office readings that mask high out-of-office blood 
pressure (masked hypertension) are common in 
black patients.35 The number of participants was 
higher in the control group than in the interven-
tion group, so the control group may have had 
more patrons who were reluctant to try prescrip-
tion drugs. Transient blood-pressure elevation 
with inflation of the arm cuff may have been 
minimized in participants in the intervention 
group, who underwent more frequent blood-
pressure measurements than participants in the 
control group. However, the magnitude of the 
intervention effect appeared substantially larger 
than that in a previous trial that we conducted 
in which similar confounding was present,4 and, 
in the present trial, the finding was not attenu-
ated in the intention-to-treat analysis.
Sustainability beyond 6 months is being exam-
ined in an ongoing extension study. Because this 
was an efficacy trial, large-scale implementation 
would require broader inclusion criteria and cost-
effective business models. Several aspects of our 
intervention (blood-pressure measurement and 
medication protocols) could be adopted by other 
health care professionals and organizations. We 
believe that the relatively large intervention effect 
indicates that such implementation research is 
warranted.11
Our prespecified blood-pressure goal of less 
than 130/80 mm Hg is consonant with the new 
2017 American blood-pressure guidelines, which 
are more stringent than previous guidelines.2 Un-
der these new guidelines, approximately 3.5 mil-
lion more black men in the United States would 
be considered to have hypertension. If the guide-
lines are correct, such men might benefit from 
this intervention.2 Because currently 58.4% of 
U.S. black men with hypertension have a blood 
pressure of 140/90 mm Hg or more, our inter-
vention offers an evidence-based model for imple-









or Relative Risk 
(95% CI)† P Value‡
Mean no. of blood-pressure medications per participant 2.6±0.9 1.4±1.4 1.9 (1.3–2.4) <0.001
Drug class
First-line drugs — no. (%)
ACE inhibitor or ARB 130 (98.5) 71 (41.5) 2.4 (2.0–2.8) <0.001
Calcium-channel blocker 125 (94.7) 56 (32.7) 3.0 (2.4–3.6) <0.001
Diuretic 61 (46.2) 49 (28.7) 1.6 (1.3–2.1) <0.001
Add-on drugs — no. (%)
Aldosterone antagonist 14 (10.6) 2 (1.2) 7.0 (2.5–19.2) <0.001
Beta-blocker 14 (10.6) 33 (19.3) 0.5 (0.3–0.8) 0.008
*  Plus–minus values are means ±SD. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker.
†  Mean difference is shown for number of blood-pressure medications per participant, and relative risk is shown for drug 
class.
‡  For number of blood-pressure medications per participant, the P value was calculated from linear mixed-effects models 
with random intercepts for clusters. For drug class, P values were calculated from generalized estimating equations 
with a compound symmetry working correlation to account for cluster effects. For all P values, the estimated between-
group difference was controlled for baseline systolic blood pressure, routine doctor, and high cholesterol level.
Table 3. Blood-Pressure Medications at 6 Months.*
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which were influenced by the Systolic Blood 
Pressure Intervention Trial (SPRINT).36 Because 
black men with hypertension often have multiple 
cardiovascular risk factors,37 marked reductions 
in blood pressure — if sustained with the use 
of our approach and then initiated more widely 
— might reduce the high rates of hypertension-
related disability and death among black men 
with hypertension in the United States.11
In conclusion, medication management that 
was delivered in barbershops by specialty-trained 
pharmacists, as compared with standard man-
agement afforded by primary care practices, re-
sulted in much larger blood-pressure reductions 
in black male patrons of those shops who had 
hypertension.
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